TY  - JOUR 
AU  - Gratacós, Jordi
AU  - Moreno Martínez-Losa, M.
AU  - Font, Pilar
AU  - Montilla Morales, Carlos Alberto
AU  - Fernández-Espartero, C.
AU  - Linares, L. F.
AU  - Brito, E.
AU  - Oliva, J. C.
AU  - Collantes-Estévez, Eduardo
PY  - 2016
SN  - 0392-856X
UR  - http://hdl.handle.net/10366/162112
AB  - [EN]To evaluate the efficacy of etoricoxib in patients with axial ankylosing spondyloarthritis (AS) refractory to traditional NSAIDs.
This was an open label, multicentric, randomised, prospective (4 weeks with and open extension to 6 months),...
LA  - eng
KW  - Ankylosing spondylitis
KW  - Etoricoxib
KW  - Anti-TNF therapy
KW  - BASDAI
KW  - BASFI
KW  - Safety
KW  - Open label
KW  - ASASBIO
KW  - ASDAS-CRP
KW  - Satisfaction
KW  - Spondylitis
KW  - Drug Substitution
KW  - Anti-Inflammatory Agents
TI  - Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs?
T2  - Clinical and Experimental Rheumatology
VL  - 34
M2  - 94
ER  -